AAAAAA

   
Results: 1-14 |
Results: 14
The endocannabinoid nervous system: unique opportunities for therapeutic intervention
Authors: Porter, AC Felder, CC
Citation: Ac. Porter et Cc. Felder, The endocannabinoid nervous system: unique opportunities for therapeutic intervention, PHARM THERA, 90(1), 2001, pp. 45-60
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
Authors: Yamada, M Miyakawa, T Duttaroy, A Yamanaka, A Moriguchi, T Makita, R Ogawa, M Chou, CJ Xia, B Crawley, JN Felder, CC Deng, CX Wess, J
Citation: M. Yamada et al., Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean, NATURE, 410(6825), 2001, pp. 207-212
Cholinergic dilation of cerebral blood vessels is abolished in M-5 muscarinic acetylcholine receptor knockout mice
Authors: Yamada, M Lamping, KG Duttaroy, A Zhang, WL Cui, YH Bymaster, FP McKinzie, DL Felder, CC Deng, CX Faraci, FM Wess, J
Citation: M. Yamada et al., Cholinergic dilation of cerebral blood vessels is abolished in M-5 muscarinic acetylcholine receptor knockout mice, P NAS US, 98(24), 2001, pp. 14096-14101
Generation and pharmacological analysis of M-2 and M-4 muscarinic receptorknockout mice
Authors: Gomeza, J Zhang, L Kostenis, E Felder, CC Bymaster, FP Brodkin, J Shannon, H Xia, B Duttaroy, A Deng, CX Wess, J
Citation: J. Gomeza et al., Generation and pharmacological analysis of M-2 and M-4 muscarinic receptorknockout mice, LIFE SCI, 68(22-23), 2001, pp. 2457-2466
Investigations into the physiological role of muscarinic M-2 and M-4 muscarinic and M-4 receptor subtypes using receptor knockout mice
Authors: Bymaster, FP Carter, PA Zhang, L Falcone, JF Stengel, PW Cohen, ML Shannon, HE Gomeza, J Wess, J Felder, CC
Citation: Fp. Bymaster et al., Investigations into the physiological role of muscarinic M-2 and M-4 muscarinic and M-4 receptor subtypes using receptor knockout mice, LIFE SCI, 68(22-23), 2001, pp. 2473-2479
Elucidating the role of muscarinic receptors in psychosis
Authors: Felder, CC Porter, AC Skillman, TL Zhang, L Bymaster, FP Nathanson, NM Hamilton, SE Gomeza, J Wess, J
Citation: Cc. Felder et al., Elucidating the role of muscarinic receptors in psychosis, LIFE SCI, 68(22-23), 2001, pp. 2605-2613
Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues
Authors: Stamer, WD Golightly, SF Hosohata, Y Ryan, EP Porter, AC Varga, E Noecker, RJ Felder, CC Yamamura, HI
Citation: Wd. Stamer et al., Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues, EUR J PHARM, 431(3), 2001, pp. 277-286
Receptor reserve of phosphoinositide-coupled muscarinic receptors in mousehippocampus in vivo
Authors: Bymaster, FP Carter, PA DeLapp, NW Calligaro, DO Felder, CC
Citation: Fp. Bymaster et al., Receptor reserve of phosphoinositide-coupled muscarinic receptors in mousehippocampus in vivo, BRAIN RES, 916(1-2), 2001, pp. 165-171
The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex
Authors: Perry, KW Nisenbaum, LK George, CA Shannon, HE Felder, CC Bymaster, FP
Citation: Kw. Perry et al., The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex, BIOL PSYCHI, 49(8), 2001, pp. 716-725
Inflammatory cytokines enhance muscarinic-mediated arachidonic acid release through p38 mitogen-activated protein kinase in A2058 cells
Authors: Wood, MW Segal, JA Mark, RJ Ogden, AM Felder, CC
Citation: Mw. Wood et al., Inflammatory cytokines enhance muscarinic-mediated arachidonic acid release through p38 mitogen-activated protein kinase in A2058 cells, J NEUROCHEM, 74(5), 2000, pp. 2033-2040
Therapeutic opportunities for muscarinic receptors in the central nervous system
Authors: Felder, CC Bymaster, FP Ward, J DeLapp, N
Citation: Cc. Felder et al., Therapeutic opportunities for muscarinic receptors in the central nervous system, J MED CHEM, 43(23), 2000, pp. 4333-4353
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Authors: Buckley , NE McCoy, KL Mezey, E Bonner, T Zimmer, A Felder, CC Glass, M Zimmer, A
Citation: Ne. Buckley et al., Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor, EUR J PHARM, 396(2-3), 2000, pp. 141-149
Determination of [S-35]guanosine-5 '-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay
Authors: DeLapp, NW McKinzie, JH Sawyer, BD Vandergriff, A Falcone, J McClure, D Felder, CC
Citation: Nw. Delapp et al., Determination of [S-35]guanosine-5 '-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay, J PHARM EXP, 289(2), 1999, pp. 946-955
1-(1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: Structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives
Authors: Jeppesen, L Olesen, PH Hansen, L Sheardown, MJ Thomsen, C Rasmussen, T Jensen, AF Christensen, MS Rimvall, K Ward, JS Whitesitt, C Calligaro, DO Bymaster, FP Delapp, NW Felder, CC Shannon, HE Sauerberg, P
Citation: L. Jeppesen et al., 1-(1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: Structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives, J MED CHEM, 42(11), 1999, pp. 1999-2006
Risultati: 1-14 |